title: Treatment of Patients with Distant Metastases from Phyllodes Tumor of the Breast.
abstract: BACKGROUND
  Here, the treatment methods and results of patients with phyllodes tumor of the breast (PT) with distant metastases at a single institution are presented.
  
  
  METHODS
  A retrospective analysis was performed on a group of 295 patients with PT treated from 1952 to 2010.
  
  
  RESULTS
  Distant metastases developed in 37 (12.5 %) patients; 3/160 (1.9 %) patients had benign PT, 6/36 (16.7 %) were considered borderline, and 28/99 (28.3 %) had malignant PT. Most frequently, the metastases were located in the lungs; 28 (75.7 %), bone 7 (18.9 %), brain 4 (10.8 %), and liver 2 (5.4 %). Metastases occurred on overage 21 months (2-57) after surgery. Patients with lung metastases were generally treated with monochemotherapy or polychemotherapy. In one patient Testosterone and in two patients resection of metastases combined with Doxorubicin were used. Patients with bones or brain metastases were treated with palliative radiotherapy only or combined with Doxorubicin. The mean survival (MS) from diagnosis of distant metastases (DM) was 7 months (2-17). The longest mean survival in patients with bones metastases was 11.8 months, the worst survival was for patients with brain metastases--2.8 months. Hormone therapy appeared to have low efficacy (MS: 2 months) as well as monochemotherapy (MS: 3-5 months). Improved MS was obtained using Doxorubicin (7 months) and Doxorubicin with Cisplatin, Cyclophosphamide, or Ifosfamide (9 months).
  
  
  CONCLUSIONS
  The prognosis of patients with DM from PT is poor. The role of surgery and irradiation of such patients is very limited. There appears to be no role for the use of hormone therapy. This study showed that polychemotherapy with Doxorubicin and Ifosfamide suggest that it might be more effective than once thought.
authors.forename: J W
authors.initials: JW
authors.lastname: Mituś
authors.forename: P
authors.initials: P
authors.lastname: Blecharz
authors.forename: T
authors.initials: T
authors.lastname: Walasek
authors.forename: M
authors.initials: M
authors.lastname: Reinfuss
authors.forename: J
authors.initials: J
authors.lastname: Jakubowicz
authors.forename: J
authors.initials: J
authors.lastname: Kulpa
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000556:secondary / Q000628:therapy; D001932:Brain Neoplasms / Q000556:secondary / Q000628:therapy; D001943:Breast Neoplasms / Q000473:pathology*; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D008175:Lung Neoplasms / Q000556:secondary / Q000628:therapy; D008875:Middle Aged; D003557:Phyllodes Tumor / Q000556:secondary* / Q000628:therapy*; D011379:Prognosis; D012189:Retrospective Studies
chemical_list: D004317:Doxorubicin; D007069:Ifosfamide